| Hazard Information | Back Directory | [Uses]
WKYMVm (TFA) is a selective formylpeptide receptor 2 (FPR2) agonist. WKYMVm has a powerful anti-inflammatory effect that can reduce lung injury and spinal cord injury. WKYMVm ameliorates obesity by regulating lipid metabolism and leptin signaling. WKYMVm is involved in the regulation of immune cells by activating FPRs, and WKYMVm can promote the chemotactic migration of immune cells and inhibit the apoptosis of phagocytes. In addition, WKYMVm may play a favorable or unfavorable role in tumors, depending on the type of tumor[1][2][3][4][5][6][7]. | [Biological Activity]
WKYMVm is a very potent agonist of formyl peptide receptor members FPR1/FPR2 (EC50 1 nM) and FPRL1/FPRL2 (75 pM and 3 nMrespectively). WKYMVm stimulation of leukocytes has been shown to elevate intracellular calciuminduce chemotaxissuperoxide generationcell killing and phagocytosis. | [References]
[1] Christophe T, et al. The synthetic peptide Trp-Lys-Tyr-Met-Val-Met-NH2 specifically activates neutrophils through FPRL1/lipoxin A4 receptors and is an agonist for the orphan monocyte-expressed chemoattractant receptor FPRL2. J Biol Chem. 2001 Jun 15;276(24):21585-93. DOI:10.1074/jbc.M007769200
[2] Christophe T, et al. Phagocyte activation by Trp-Lys-Tyr-Met-Val-Met, acting through FPRL1/LXA4R, is not affected by lipoxin A4. Scand J Immunol. 2002 Nov;56(5):470-6. DOI:10.1046/j.1365-3083.2002.01149.x
[3] Zhang W, et al. WKYMVm/FPR2 Alleviates Spinal Cord Injury by Attenuating the Inflammatory Response of Microglia. Mediators Inflamm. 2022 Jul 27;2022:4408099. DOI:10.1155/2022/4408099
[4] Kim YE, et al. WKYMVm hexapeptide, a strong formyl peptide receptor 2 agonist, attenuates hyperoxia-induced lung injuries in newborn mice. Sci Rep. 2019 May 2;9(1):6815. DOI:10.1038/s41598-019-43321-4
[5] Kang JH, et al. WKYMVm ameliorates obesity by improving lipid metabolism and leptin signalling. J Cell Mol Med. 2023 Sep;27(18):2782-2791. DOI:10.1111/jcmm.17910
[6] Yang Y, et al. WKYMVm Works by Targeting Immune Cells. J Inflamm Res. 2023 Jan 6;16:45-55. DOI:10.2147/JIR.S390394
[7] Ma H, et al. Therapeutic potential of WKYMVm in diseases. Front Pharmacol. 2022 Sep 2;13:986963. DOI:10.3389/fphar.2022.986963 |
|
| Company Name: |
Merck KGaA
|
| Tel: |
21-20338288 |
| Website: |
www.sigmaaldrich.cn |
| Company Name: |
Biorbyt Ltd.
|
| Tel: |
+44 (0)1223 859 353 |
| Website: |
http://www.biorbyt.com |
| Company Name: |
MedChemExpress
|
| Tel: |
021-58955995 |
| Website: |
www.medchemexpress.com |
|